New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents

Medicinal Chemistry

Volumn 9, Issue 8, 2013, Pages 1051-1057

  Tung, Truong Thanh ^a   Oanh, Dao Thi Kim ^a   Dung, Phan Thi Phuong ^a   Hue, Van Thi My ^a   Park, Sang Ho ^b   Han, Byung Woo ^b   Kim, Youngsoo ^c   Hong, Jin Tae ^c   Han, Sang Bae ^c   Nam, Nguyen Hai ^a  

^a HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^b Seoul National University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Benzothiazole; Heterocycle; Histone deacetylase inhibitors

Indexed keywords

2 AMINOTHIAZOLE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; ENTINOSTAT; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N [6 (TRIFLUOROMETHYL)BENZO[D]THIAZOL 2 YL]N HYDROXYOCTANEDIAMIDE; N' (6 CHLOROBENZO[D]THIAZOL 2 YL) N HYDROXYOCTANEDIAMIDE; N' (THIAZOL 2 YL) N HYDROXYOCTANEDIAMIDE; OXAMFLATIN; PANOBINOSTAT; THIAZOLE DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; BENZOTHIAZOLE; HISTONE DEACETYLASE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG SYNTHESIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; MCF 7 CELL LINE; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84887259628     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/15734064113099990027     Document Type: Article

References (12)

1. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21.
2. De Ruijter, A.J.M.; Gennip, A.H.V.; Caron, H.N.; Kemp, S.; Kuilenburg, A.B.P.V. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-739.
3. Dokmanovic, M.; Marks, P.A. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs. 2005, 14, 1497-1511.
4. Glaser, K.B. HDAC inhibitors: clinical update and mechanismbased potential. Biochem. Pharmacol. 2007, 74, 659-871.
5. Dallavalle, S.; Cincinelli, R.; Nannei, R.; Merlini, L.; Morini, G.; Penco, S.; Pisano, C.; Vesci, L.; Barbarino, M.; Zuco, V.; De Cesare, M.; Zunino, F. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem. 2009, 44, 1900-1912.
6. Bracker, T.U.; Sommer, A.; Fichtner, I.; Faus, H.; Haendler, B.; Hess-Stumpp, H. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int. J. Oncol. 2009, 35, 909-920.
7. Oanh, D.T.K.; Hai, H.V.; Hue, V.T.M.; Park, S.H.; Kim, H.J.; Han, B.W.; Kim, H.S.; Hong, J.T.; Han, S.B.; Nam, N.H. Benzothiazolecontaining hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg. Med. Chem. Lett. 2011, 21, 7509-7512.
8. Somoza, J.R.; Skene, R.J.; Katz, B.A.; Mol, C.; Ho, J.D.; Jennings, A.J.; Luong, C.; Arvai, A.; Buggy, J.J.; Chi, E.; Tang, J.; Sang, B.C.; Verner, E.; Wynands, R.; Leahy, E.M.; Dougan, D.R.; Snell, S.; Navre, M.; Knuth, M.W.; Swanson, R.V.; McRee, D.E.; Tari, L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
9. Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455-461.
10. Skehan, P.; Storeng, R.; Scudiero, D.; Monk, A.; MacMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
11. Nam, N.H.; Kim, Y.; You, Y.J.; Hong, D.H.; Kim, H.M.; Ahn, B.Z. New Contituents from Crinum latifolium with Inhibitory Activity against Tube-like Formation of Human Umbilical Endothelial Cells. Nat. Prod. Res. 2004, 18, 485-491.
12. Wu, L.; Smythe, A.M.; Stinson, S.F.; Mullendore, L.A.; Monks, A.; Scudiero, D.A.; Paull, K.D.; Koutsoukos, A.D.; Rubinstein, L.V.; Boyd, M.R.; Shoemaker, R.H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 1992, 52, 3029-3034.